000 02237nam a2200421 i 4500
999 _c255740
_d255740
001 ocn960812476
003 BD
005 20171106215307.0
007 he bmb024bbca
008 161017s2016 dcu bb f000 0 eng c
040 _aPUCPR
_beng
_erda
_cGPO
042 _apcc
043 _an-us---
049 _aBDDF
050 1 4 _aKF27
_b.E553 2014
074 _a1019-B-01 (MF)
086 0 _aY 4.C 73/8:113-132
088 _aSerial no. 113-132 (United States. Congress. House. Committee on Energy and Commerce)
099 _aY 4.C 73/8:113-132
110 1 _aUnited States.
_bCongress.
_bHouse.
_bCommittee on Energy and Commerce.
_bSubcommittee on Health,
_eauthor.
245 1 0 _aExamining concerns regarding FDA's proposed changes to generic drug labeling :
_bhearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Thirteenth Congress, second session, April 1, 2014.
264 1 _aWashington :
_bU.S. Government Publishing Office,
_c2016.
300 _av, 146 pages ;
_c24 cm
336 _atext
_btxt
_2rdacontent
337 _amicroform
_bh
_2rdamedia
338 _amicrofiche
_bhe
_2rdacarrier
500 _aShipping list no.: 2016-0177-M.
500 _aPaper version available for sale by the Superintendent of Documents, U.S. Government Publishing Office.
500 _a"Serial No. 113-132."
500 _aCRDP Project record.
504 _aIncludes bibliographical references.
533 _aMicrofiche.
_b[Washington, D.C.] :
_cU.S. Government Printing Office,
_d[2016]
_e2 microfiches : negative.
650 0 _aGeneric drugs
_xLabeling
_zUnited States.
650 0 _aDrugs
_xSafety regulations
_zUnited States.
650 0 _aWarning labels
_xGovernment policy
_zUnited States.
655 7 _aLegislative hearings.
_2lcgft
776 0 8 _iPrint version:
_aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health.
_tExamining concerns regarding FDA's proposed changes to generic drug labeling
_w(DLC) 2015464829
_w(OCoLC)946536358
776 0 8 _iOnline version:
_aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health.
_tExamining concerns regarding FDA's proposed changes to generic drug labeling
_w(OCoLC)945734630
942 _2sudocs
_c12